90 related articles for article (PubMed ID: 2825982)
61. Intracellular drug concentration and DNA damage in human childhood leukemic cells exposed to doxorubicin.
Catapano CV; Ubezio P; Rossi V; Conter V; Jancovich M; D'Incalci M
Biochem Pharmacol; 1988 May; 37(9):1863-4. PubMed ID: 3377855
[No Abstract] [Full Text] [Related]
62. Chemotherapy activates inflammasomes to cause inflammation-associated bone loss.
Wang C; Kaur K; Xu C; Abu-Amer Y; Mbalaviele G
Elife; 2024 Apr; 13():. PubMed ID: 38602733
[TBL] [Abstract][Full Text] [Related]
63. Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts.
Mehta RK; Pal S; Kondapi K; Sitto M; Dewar C; Devasia T; Schipper MJ; Thomas DG; Basrur V; Pai MP; Morishima Y; Osawa Y; Pratt WB; Lawrence TS; Nyati MK
Clin Cancer Res; 2020 Oct; 26(19):5246-5257. PubMed ID: 32718999
[TBL] [Abstract][Full Text] [Related]
64. Increased uptake of doxorubicin by cells undergoing heat stress does not explain its synergistic cytotoxicity with hyperthermia.
Sharma A; Özayral S; Caserto JS; Ten Cate R; Anders NM; Barnett JD; Kandala SK; Henderson E; Stewart J; Liapi E; Rudek MA; Franken NAP; Oei AL; Korangath P; Bunz F; Ivkov R
Int J Hyperthermia; 2019; 36(1):712-720. PubMed ID: 31345068
[No Abstract] [Full Text] [Related]
65. A Nucleolar Stress-Specific p53-miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network.
Fujiwara Y; Saito M; Robles AI; Nishida M; Takeshita F; Watanabe M; Ochiya T; Yokota J; Kohno T; Harris CC; Tsuchiya N
EBioMedicine; 2018 Jul; 33():33-48. PubMed ID: 30049386
[TBL] [Abstract][Full Text] [Related]
66. Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of α-Tubulin and Inhibition of Microtubule Formation.
Zhang YZ; Chen X; Fan XX; He JX; Huang J; Xiao DK; Zhou YL; Zheng SY; Xu JH; Yao XJ; Liu L; Leung EL
Molecules; 2016 Mar; 21(3):374. PubMed ID: 26999101
[TBL] [Abstract][Full Text] [Related]
67. Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts.
Ahsan A; Ramanand SG; Bergin IL; Zhao L; Whitehead CE; Rehemtulla A; Ray D; Pratt WB; Lawrence TS; Nyati MK
Neoplasia; 2014 Feb; 16(2):105-14. PubMed ID: 24709418
[TBL] [Abstract][Full Text] [Related]
68. Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization.
Ahsan A; Ray D; Ramanand SG; Hegde A; Whitehead C; Rehemtulla A; Morishima Y; Pratt WB; Osawa Y; Lawrence TS; Nyati MK
J Biol Chem; 2013 Sep; 288(37):26879-86. PubMed ID: 23897823
[TBL] [Abstract][Full Text] [Related]
69. Drug-mediated inhibition of Fli-1 for the treatment of leukemia.
Li YJ; Zhao X; Vecchiarelli-Federico LM; Li Y; Datti A; Cheng Y; Ben-David Y
Blood Cancer J; 2012 Jan; 2(1):e54. PubMed ID: 22829238
[TBL] [Abstract][Full Text] [Related]
70. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Fujimoto S; Chikazawa H
Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
[TBL] [Abstract][Full Text] [Related]
71. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Ellis AL; Nowak B; Plunkett W; Zwelling LA
Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
[TBL] [Abstract][Full Text] [Related]
72. Anthracycline antibiotics in cancer therapy. Focus on drug resistance.
Booser DJ; Hortobagyi GN
Drugs; 1994 Feb; 47(2):223-58. PubMed ID: 7512899
[TBL] [Abstract][Full Text] [Related]
73. Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology.
Wierzba K; Sugimoto Y; Matsuo K; Toko T; Takeda S; Yamada Y; Tsukagoshi S
Jpn J Cancer Res; 1990 Aug; 81(8):842-9. PubMed ID: 2144516
[TBL] [Abstract][Full Text] [Related]
74. Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.
Fisher GR; Patterson LH
Cancer Chemother Pharmacol; 1992; 30(6):451-8. PubMed ID: 1394801
[TBL] [Abstract][Full Text] [Related]
75. Reduction of doxorubicin cytotoxicity by ouabain: correlation with topoisomerase-induced DNA strand breakage in human and hamster cells.
Lawrence TS
Cancer Res; 1988 Feb; 48(3):725-30. PubMed ID: 2825982
[TBL] [Abstract][Full Text] [Related]
76. Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment.
Lawrence TS; Canman CE; Maybaum J; Davis MA
Cancer Res; 1989 Sep; 49(17):4775-9. PubMed ID: 2547516
[TBL] [Abstract][Full Text] [Related]
77. The influence of Na+,K(+)-pump blockade on doxorubicin-mediated cytotoxicity and DNA strand breakage in human tumor cells.
Lawrence TS; Davis MA
Cancer Chemother Pharmacol; 1990; 26(3):163-7. PubMed ID: 2162743
[TBL] [Abstract][Full Text] [Related]
78. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.
De Graff WG; Myers LS; Mitchell JB; Hahn SM
Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789
[TBL] [Abstract][Full Text] [Related]
79. Reduction by caffeine of adriamycin-induced cell killing and DNA damage in Chinese hamster cells: correlation with modulation in intracellular adriamycin content.
Iliakis G; Lazar W
Cancer Res; 1987 May; 47(9):2224-9. PubMed ID: 3552213
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
